Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 308

1.

Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.

Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H.

J Neurosci. 2006 Sep 27;26(39):10068-78.

2.

Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence.

Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ischiropoulos H.

J Biol Chem. 2007 Oct 26;282(43):31621-30. Epub 2007 Sep 4.

3.

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. Epub 2002 Jul 16.

4.

Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.

Park SS, Schulz EM, Lee D.

Eur J Neurosci. 2007 Dec;26(11):3104-12. Epub 2007 Nov 14.

PMID:
18005066
5.

Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.

Pham CL, Leong SL, Ali FE, Kenche VB, Hill AF, Gras SL, Barnham KJ, Cappai R.

J Mol Biol. 2009 Apr 3;387(3):771-85. doi: 10.1016/j.jmb.2009.02.007. Epub 2009 Feb 11.

PMID:
19361420
6.

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

Gerard M, Deleersnijder A, Daniëls V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, Debyser Z, Baekelandt V.

J Neurosci. 2010 Feb 17;30(7):2454-63. doi: 10.1523/JNEUROSCI.5983-09.2010.

7.

Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.

Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK.

J Neurosci. 2004 Aug 18;24(33):7400-9.

8.

Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.

Peneder TM, Scholze P, Berger ML, Reither H, Heinze G, Bertl J, Bauer J, Richfield EK, Hornykiewicz O, Pifl C.

Neuroscience. 2011 Apr 28;180:280-92. doi: 10.1016/j.neuroscience.2011.02.017. Epub 2011 Feb 16.

PMID:
21333719
9.
10.

Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells.

Kim SS, Moon KR, Choi HJ.

Arch Pharm Res. 2011 May;34(5):837-45. doi: 10.1007/s12272-011-0518-0. Epub 2011 Jun 9.

PMID:
21656370
11.

Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors.

Wislet-Gendebien S, Visanji NP, Whitehead SN, Marsilio D, Hou W, Figeys D, Fraser PE, Bennett SA, Tandon A.

BMC Neurosci. 2008 Sep 22;9:92. doi: 10.1186/1471-2202-9-92.

12.

Fe(II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay.

Martin FL, Williamson SJ, Paleologou KE, Hewitt R, El-Agnaf OM, Allsop D.

J Neurochem. 2003 Nov;87(3):620-30.

13.

Different species of alpha-synuclein oligomers induce calcium influx and seeding.

Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M.

J Neurosci. 2007 Aug 22;27(34):9220-32.

14.

Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.

Mishizen-Eberz AJ, Guttmann RP, Giasson BI, Day GA 3rd, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR.

J Neurochem. 2003 Aug;86(4):836-47.

15.

Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations.

Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM.

J Biol Chem. 2005 Jun 3;280(22):21212-9. Epub 2005 Apr 6.

16.

Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.

Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T.

J Neurosci. 2011 Nov 16;31(46):16884-94. doi: 10.1523/JNEUROSCI.3967-11.2011.

17.
18.

Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration.

Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA.

J Neurosci. 2003 Apr 15;23(8):3095-9.

20.

Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.

Maingay M, Romero-Ramos M, Carta M, Kirik D.

Neurobiol Dis. 2006 Sep;23(3):522-32. Epub 2006 Jun 30.

PMID:
16806952

Supplemental Content

Support Center